{
  "slug": "glp1-microdosing",
  "file": "glp1-microdosing.review.md (shipped review; second adversarial pass)",
  "authoring_model": "Sol 6.1",
  "adversarial_reviewer": "Claude Opus 5.5 (Anthropic)",
  "date": "2026-11-02",
  "level_before": "Γ",
  "level_after": "Γ",
  "confidence_before": "Moderate",
  "confidence_after": "Moderate",
  "pmids_checked": 59,
  "pmids_failed": 0,
  "claims_spot_checked": 17,
  "findings": [
    {
      "id": "A1",
      "severity": "Major",
      "location": "Evidence and causal interpretation; decisive-perturbation inventory; SC2 decision; Momentum",
      "original": "(absent)",
      "corrected": "Add inventory item: federated EHR analysis, 814 adults with >=3 0.25 mg-only semaglutide prescriptions spanning >=6 months; mean 12-month weight change -2.2% (vs -5.5% sustained 2.5 mg tirzepatide). Observational, no placebo, prescription-selected; closest real-world record of sustained sub-0.5 mg weekly exposure; does not show >=5% loss. Add to SC2 rationale and Momentum artifact.",
      "evidence": "PMID 42857675 (Murugadoss et al., Biol Methods Protoc 2026, DOI 10.1093/biomethods/bpag048, e-pub 2026-08-31, before cutoff). Not in scorecard. Only sizeable on-exposure dataset; points against the claim. SC2 stays Gamma (no placebo arm)."
    },
    {
      "id": "A2",
      "severity": "Minor",
      "location": "Evidence and causal interpretation para 2; steelman (above)",
      "original": "Every semaglutide injection in that trial was daily. Multiplying or dividing its milligrams cannot manufacture a weekly exposure trial.",
      "corrected": "Every semaglutide injection in that trial was daily, and the preregistered scope excludes daily-to-weekly conversion. Pharmacologically, however, a sponsor exposure-response model found that systemic exposure, not schedule, explained weight trajectories across the daily 0.05-0.4 mg and weekly 2.4 mg trials; the 0.05 mg daily arm (0.35 mg per week cumulatively) is therefore the closest exposure-matched randomised evidence, and it is the strongest argument a Delta steelman could make.",
      "evidence": "PMID 37424165 (Strathe et al., Diabetes Obes Metab 2023, DOI 10.1111/dom.15211): exposure 'consistently explained the weight-loss trajectories across trials and dosing regimens'. PMID 30122305: 0.05 mg daily -6.0% vs -2.3% placebo at 52 weeks. Scope exclusion stands; no level change."
    },
    {
      "id": "A3",
      "severity": "Minor",
      "location": "SC4 decision; Falsification; inventory [8]; best-supported rival",
      "original": "In PMID 42323166, intake and weight differences persist at 40/60 weeks while appetite and food-preoccupation contrasts lose significance.",
      "corrected": "In PMID 42323166, intake differences persist at 20/40/60 weeks while hunger and food-preoccupation contrasts lose significance after week 20; food-reward responsiveness (Power of Food Scale), the measure closest to the food-noise construct, still differed at week 40 and only at week 60 did no subjective contrast remain.",
      "evidence": "PMID 42323166 abstract: greater reductions in responsiveness to the rewarding value of food at weeks 20 and 40. Dissociation overstated. SC4 stays Gamma."
    },
    {
      "id": "A4",
      "severity": "Minor",
      "location": "Evidence and causal interpretation para 4; inventory [32],[50]; card [50]",
      "original": "None satisfies the registered initiation claim. / do not test below-0.5 mg once-weekly initiation",
      "corrected": "None satisfies the registered maintenance claim. / do not test below-0.5 mg once-weekly maintenance against placebo",
      "evidence": "Registered claim and SC2 concern maintenance doses; the review alternates between initiation and maintenance readings. Internal contradiction; no level change."
    },
    {
      "id": "A5",
      "severity": "Minor",
      "location": "reader-summary.json limitations",
      "original": "59 primary reports with 3 selected partial-body examinations; density, heterogeneous controls and incomplete access set the confidence, not correctness.",
      "corrected": "59 primary reports examined. Moderate confidence rests on evidence density and reproducibility, not reading access: no study tests the registered sub-0.5 mg weekly maintenance exposure, the dose-adjacent reports are uncontrolled and response-selected, and muscle and food-noise outcomes conflict or rest on recall.",
      "evidence": "GM-3 corrected the scorecard rationale under lead policy; lay summary still prints the struck wording."
    },
    {
      "id": "A6",
      "severity": "Minor",
      "location": "Decisive-perturbation inventory, tally sentence",
      "original": "Tally: 0 positive qualifying study units across scoped subclaims; 11 screened discriminating contrast units.",
      "corrected": "Same counts plus: The eleven discriminating contrasts ([22],[30],[32],[34],[50],[51],[52],[53],[54],[55],[58]) are a different set from the twelve decisive perturbations printed above.",
      "evidence": "Scorecard evidence_inventory: decisive_perturbation true for the 12 printed items; discriminating_contrast true for 11 incl. unprinted [30],[54],[55], excluding [1],[2],[8],[19]. [8], the principal falsification source, is not flagged discriminating; lead may check."
    },
    {
      "id": "A7",
      "severity": "Minor",
      "location": "AT A GLANCE, Causal role cell",
      "original": "epiphenomenon",
      "corrected": "epiphenomenon (framework label for no demonstrated dependency at the exact registered dose; standard-dose semaglutide is causally effective)",
      "evidence": "Lay readers will read 'epiphenomenon' as 'drug does nothing'; caveat appears only in the Final score section."
    },
    {
      "id": "A8",
      "severity": "Minor",
      "location": "Falsification and pitfalls, strict microdose equivalence paragraph",
      "original": "No experimental falsification of exact-dose efficacy was examined.",
      "corrected": "No experimental falsification of exact-dose efficacy was examined. Randomised dose-response evidence nevertheless runs against comparability: weight loss rose monotonically from 0.05 to 0.4 mg daily, weekly dose-finding was dose dependent, and 2.0 mg exceeded 1.0 mg weekly, while gastrointestinal events were dose related. Lower doses plausibly reduce adverse effects but, on every randomised dose comparison examined, also reduce weight loss.",
      "evidence": "PMID 30122305; PMID 26358288; PMID 34293304 (SUSTAIN FORTE -6.9 vs -6.0 kg). All already cited. SC3 stays Alpha."
    },
    {
      "id": "A9",
      "severity": "Minor",
      "location": "Cap audit field-valid definitions, 30 literal Gamma hard-rule paragraphs, 5 Delta ladder lines",
      "original": "Verbatim aging-rubric text (lifespan/healthspan extension; ROS, NAD, mitochondrial, senescence hard rules) printed 35 times as operative criteria",
      "corrected": "One sentence stating rubric 06 (metabolism-aging) is used by adaptation, its lifespan criteria and aging-marker hard rules do not apply to a weight-loss claim, and the applied adaptations for SC1-SC5 are the operative thresholds.",
      "evidence": "rubric_routing.primary_rubric = 06-metabolism-aging.md; review says 'Lifespan is not imposed'. 'Satisfied: no' against a lifespan criterion is misleading (SELECT changed a hard outcome at 2.4 mg). Declared adaptation; no level change."
    },
    {
      "id": "A10",
      "severity": "Editorial",
      "location": "Stability; Knowledge gaps",
      "original": "(absent)",
      "corrected": "Add: named de-escalation trials registered (REST NCT07294950, primary completion 2028-09; NCT07783854, primary completion 2027-12); they test tapering from 1-1.7 mg, not sustained sub-0.5 mg maintenance vs placebo, so Stability remains Stable.",
      "evidence": "ClinicalTrials.gov records retrieved 2026-11-02."
    },
    {
      "id": "A11",
      "severity": "Editorial",
      "location": "PROPOSED DECISIVE EXPERIMENTS readout line",
      "original": "outcomes.. Controls / measurement.. Supporting / SC3.. Falsifying / equivalence..",
      "corrected": "single full stops",
      "evidence": "Renderer joins pre-terminated strings with an extra period."
    }
  ],
  "rejected_findings": [
    "Best-supported rival label correct: models_evaluated[0] is M1 (nominal, rank 3); AT A GLANCE names M2 (rank 1, non-nominal). GM-1 applied.",
    "Primary-subclaim aggregation SC2=Gamma matches headline; weakest-link sensitivity Alpha follows from SC3.",
    "SC2 Beta/Gamma/Delta boundary: no placebo-controlled sustained sub-0.5 mg weekly trial exists; Gamma stands, Beta considered and rejected.",
    "Tournament not a strawman field: M3 and M4 are genuine alternative explanations; M2 is compatible rather than strict rival.",
    "All checked figures (STEP 1-4, FLEX-SEMA, INFORM, SEMALEAN, Ren, Tzoulis, Wong, Bolek, STEP UP) match abstracts.",
    "GM-2, GM-3, GM-4 confirmed applied; no residual fused numeral tokens.",
    "Momentum and Stability values correct; A1/A10 are content additions only.",
    "No retraction, expression of concern or collective-author defect; year +/-1 at refs 7, 22, 27, 29, 51, 58 is e-pub vs print."
  ],
  "new_sources_verified": [
    {
      "pmid": "42857675",
      "doi": "10.1093/biomethods/bpag048",
      "use": "A1"
    },
    {
      "pmid": "37424165",
      "doi": "10.1111/dom.15211",
      "use": "A2"
    },
    {
      "nct": "NCT07294950",
      "use": "A10"
    },
    {
      "nct": "NCT07783854",
      "use": "A10"
    }
  ],
  "scorecard_changed": false,
  "files_edited": [],
  "approval": "Not approved as shipped pending A1; recommended once A1 applied and A2-A9 applied or explicitly declined. Level and confidence endorsed.",
  "residual_limitations": [
    "Spot checks at abstract depth; FLEX-SEMA body figures not re-read.",
    "A1 EHR cohort read at abstract depth only."
  ]
}